Login to Your Account



FDA, Experts Debate Minimal Residual Disease as Endpoint

By Marie Powers
Staff Writer

Thursday, April 19, 2012
The first readily apparent conclusion from Wednesday's FDA workshop on the use of minimal residual disease (MRD) as a surrogate endpoint in acute lymphoblastic leukemia (ALL) is that technical implementation issues continue to lag and could stifle the obvious clinical interest in developing such efficacy biomarkers.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription